Decided to stop development of this compound globally

The purpose of this study is to evaluate the safety and tolerability after repeated ascending doses of AZD7325 in Japanese healthy male subjects.

Inclusion Criteria:

• Japanese subjects

Exclusion Criteria:

• Significant illness, as judged by the investigator, within 2 weeks of Day 1
• Enrollment in another concurrent investigational study or intake of an investigational drug within 4 months prior to the screening visit
• Blood loss in excess of 200 mL within 30 days of Day 1, in excess of 400 mL within 90 days of Day 1, or in excess of 1200 mL within 1 year of Day 1
• Clinically relevant abnormalities in physical examinations, vital signs, clinical chemistry, hematology or urinalysis as judged by the investigator and/or sponsor